Varex Imaging
Varex Imaging's revenue rose 4.1% to $845 million in fiscal 2025. Its operating margin was −3.3%, down from 4.0% a year earlier. Free cash flow was $19 million, down 7.8%. The diluted share count rose 1.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Varex Imaging does
Varex Imaging makes X-ray imaging components. It sells them mostly to equipment makers, called OEMs, which build the parts into their own X-ray systems. The company says a substantial majority of medical X-ray OEMs are its customers, and that many have been customers for over 35 years.
It has two reportable segments. The Medical segment designs, makes, sells and services X-ray tubes, flat panel and photon counting detectors, high voltage connectors, software, generators and other parts. These are used in imaging such as CT, mammography, cardiac, dental and fluoroscopy. The Industrial segment supplies components for security and cargo screening, industrial quality inspection, and analysis and measurement in manufacturing.
Varex sells in three regions: the Americas, EMEA (Europe, the Middle East, India and Africa) and APAC. It says it is one of the largest independent X-ray imaging component suppliers. It has engineering, manufacturing and service sites in North America, Europe and Asia. It says it competes in highly competitive industries with pricing pressure, and that some of its OEM customers are also its competitors.
Its biggest risks, as it describes them
- Tariffs and changes in import and export rules, including those affecting its sales to China.
- Selling to a limited number of OEM customers, many of which are also competitors.
- Customer order forecasts that change often, making demand hard to predict.
- Strong competition and pricing pressure in its industries.
- New generations of products that may not be developed or sold successfully.
Income statement
From fiscal 2016 to 2023, earnings per share fell 7.3% a year and net income 5.1% a year, as new shares raised the share count by 33% and diluted each share's earnings. Varex Imaging then lost money in fiscal 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 145 | 89 | 194 | 200 | 155 |
| Debt incl. finance leases | 435 | 415 | 443 | 450 | 374 |
| Net debt (negative means net cash) | 290 | 325 | 249 | 249 | 218 |
| Net debt to EBITDA | 2.6x | 2.7x | 2.3x | 3.9x | — |
| Debt to equity | 0.9x | 0.8x | 0.8x | 0.8x | 0.8x |
| Interest coverage | 1.8x | 2.2x | 2.6x | 1.1x | −0.8x |
| Current ratio | 3.3x | 3.5x | 4.0x | 3.3x | 3.4x |
| Quick ratio | 2.0x | 1.8x | 2.3x | 2.0x | 1.8x |
Cash flow
Projections
Project Varex Imaging's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Varex Imaging reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 4 of 9 | 6 of 9 |
| Rule of 40 | 13.8% | −6.7% | 6.4% |
| Altman Z'' | 4.23 | 3.66 | 3.33 |
| Accruals ratio | −5.0% | −7.8% | −9.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Pass | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 6 of 9 | 4 of 9 | 6 of 9 |
Compare
Put Varex Imaging side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Varex Imaging | FY25 | 4.1% | −3.3% | 2.2% | −2.9% | — | 6 | |
| Inspire Medical Systems | FY25 | 13.6% | 5.6% | 8.6% | 14.2% | −4.8x | 5 | Compare |
| Alphatec | FY25 | 24.9% | −10.8% | 0.4% | −14.3% | — | 5 | Compare |
| iRhythm | FY25 | 26.2% | −7.7% | 4.6% | −12.4% | — | 5 | Compare |
| Tandem Diabetes Care | FY25 | 7.9% | −18.4% | −2.9% | −85.5% | — | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 620 | 698 | 773 | 781 | 738 | 818 | 859 | 893 | 811 | 845 |
| Revenue growth | −1.9% | 12.6% | 10.8% | 0.9% | −5.4% | 10.8% | 5.0% | 4.0% | −9.2% | 4.1% |
| Gross profit | 248 | 254 | 254 | 257 | 190 | 272 | 284 | 290 | 257 | 290 |
| Research and development | 54 | 67 | 83 | 78 | 79 | 72 | 77 | 85 | 87 | 91 |
| Operating income | 109 | 84 | 44 | 46 | −34 | 74 | 88 | 77 | 32 | −28 |
| Net income | 68 | 52 | 28 | 16 | −58 | 17 | 30 | 47 | −49 | −70 |
| Diluted EPS (US$) | 1.82 | 1.36 | 0.72 | 0.40 | −1.49 | 0.43 | 0.73 | 1.07 | −1.20 | −1.70 |
| Diluted shares (millions) | 38 | 38 | 38 | 39 | 39 | 40 | 42 | 50 | 41 | 41 |
| Cash flow | ||||||||||
| Cash from operations | 74 | 75 | 85 | 72 | 13 | 93 | 17 | 108 | 47 | 42 |
| Capital expenditure | 29 | 20 | 20 | 20 | 24 | 15 | 21 | 21 | 27 | 23 |
| Free cash flow | 45 | 55 | 65 | 52 | −10 | 78 | −4 | 88 | 20 | 19 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 1 | 272 | 5 | 70 | 2 | 0 | 0 | 1 | 1 | 0 |
| Stock-based compensation | 10 | 8 | 10 | 12 | 13 | 14 | 14 | 14 | 15 | 15 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 36 | 83 | 52 | 30 | 101 | 145 | 89 | 194 | 200 | 155 |
| Debt incl. finance leases | 0 | 484 | 390 | 395 | 456 | 435 | 415 | 443 | 450 | 374 |
| Total assets | 622 | 1,040 | 988 | 1,039 | 1,140 | 1,148 | 1,184 | 1,250 | 1,214 | 1,107 |
| Total liabilities | 86 | 650 | 548 | 580 | 674 | 651 | 638 | 669 | 670 | 621 |
| Shareholders' equity | 526 | 379 | 426 | 445 | 452 | 483 | 533 | 568 | 529 | 473 |
| Margins and ratios | ||||||||||
| Gross margin | 40.1% | 36.3% | 32.8% | 32.9% | 25.8% | 33.2% | 33.0% | 32.5% | 31.7% | 34.4% |
| Operating margin | 17.6% | 12.0% | 5.8% | 5.8% | −4.6% | 9.1% | 10.3% | 8.6% | 4.0% | −3.3% |
| Net margin | 11.1% | 7.4% | 3.6% | 2.0% | −7.8% | 2.1% | 3.5% | 5.3% | −6.0% | −8.3% |
| Free cash flow margin | 7.3% | 7.9% | 8.4% | 6.7% | −1.4% | 9.5% | −0.5% | 9.8% | 2.5% | 2.2% |
| Rule of 40 (growth + FCF margin) | 5.4% | 20.5% | 19.2% | 7.6% | −6.8% | 20.3% | 4.5% | 13.8% | −6.7% | 6.4% |
| Return on capital | — | 9.2% | 5.8% | 4.2% | −3.3% | 5.8% | 7.4% | 9.1% | 2.0% | −2.9% |
| Return on equity | — | 11.4% | 6.8% | 3.6% | −12.9% | 3.7% | 6.0% | 8.6% | −8.9% | −14.0% |
| Return on assets | — | 6.2% | 2.7% | 1.5% | −5.3% | 1.5% | 2.6% | 3.9% | −4.0% | −6.1% |
| Net debt to EBITDA | −0.3x | 3.6x | 3.9x | 4.3x | 61.3x | 2.6x | 2.7x | 2.3x | 3.9x | — |